Login to Your Account

Strong quarter for blue chip biopharmas and drug developers

By Peter Winter

Monday, October 9, 2017

Biopharmaceutical companies continue to enjoy a banner year, and the sector as a whole remains a favorite with investors, a fact confirmed by Jefferies analyst Michael Yee, who wrote that "the biotech sector [is] seeing an increase in money flow and better performance vs. the broader market and other health care sectors."

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription